‘Self-Taught’ AI Tool Helps to Diagnose & Predict Severity of Common Lung Cancer
“A computer program based on data from nearly a half-million tissue images and powered by artificial intelligence (AI) can accurately diagnose in cases of adenocarcinoma, the most common form of lung cancer, a new study shows. Researchers at NYU Langone Health’s Perlmutter Cancer Center and the University of Glasgow, in Scotland, developed and tested the program. They say that because it incorporates structural features of tumors from 452 adenocarcinoma patients, who are among the more than 11,000 patients in the U.S. National Cancer Institute’s Cancer Genome Atlas, the program offers an unbiased, detailed, and reliable second opinion for patients and oncologists about the presence of the cancer and the likelihood and timing of its return, also known as its prognosis.”
Yale Cancer Center sees gains in lung cancer treatment
“NEW HAVEN, Conn. (WTNH) — The Yale Cancer Center has seen immense progress in the last 20 years in how lung cancer is treated. “The good news is that we’re diagnosing it earlier,” said Dr. Roy Herbst, the deputy director of the center. “The good news is that we have more specific therapies.” What those therapies are, and how they can best be used, was discussed at the annual lung cancer SPORE (specialized program of research excellence) workshop this week.”
MSU researchers discover honeybees can detect lung cancer
“Michigan State University researchers have discovered that honeybees can detect biomarkers or chemical concentrations associated with lung cancer in human breath. The researchers have also shown that the honeybees can distinguish between different lung cancer cell types using only the ‘smell’ of the cell cultures. These findings could be used as a model for developing new tests to diagnose lung cancer early.”
Cost of Care Discussions Rarely Documented for Patients with Advanced Cancer, New Study Shows
“ATLANTA, June 13, 2024 — A new large population-based pilot study led by researchers at the American Cancer Society (ACS) and the National Cancer Institute shows cost discussions were infrequently documented in medical records of patient diagnosed with advanced non-small cell lung cancer (NSCLC) and melanoma, which may hinder identifying patient financial needs and tracking outcomes of associated referrals. The findings will be published today in the journal Cancer.”
Why many people with lung cancer who have never smoked don’t respond well to treatments
“Researchers report that people who have never smoked are less likely to respond to standard treatment for non-small cell lung cancer. Researchers say a combination of two genetic mutations may make cancer cells in non-smokers more resistant to treatment. They add that new diagnostic tests and targeted therapy are needed to address treatment-resistant cases.”
Lung cancer screening program identifies airways disease in previously undiagnosed COPD
“Key takeaways: More individuals with vs. without a history of COPD had pulmonary comorbidities on low-dose CT. Age, gender and smoking status significantly differed between these two groups.”
Updates from ASCO 2024
“Each year, The Patient Story attends a handful of cancer conferences to meet with experts on the frontlines of cancer care and report on developments that matter to patients. We’ve reported on ASH, SABCS, and ASCO. The American Society for Clinical Oncology (ASCO), established in 1964, plays a pivotal role in the global fight against cancer. It was held from May 31 to June 4, 2024. This page provides updates from our attendance.”
Dr Jani on the Effects of Tobacco and Air Pollution on Lung Cancer Mortality
“Overall, although progress has been made to reduce tobacco-related lung cancer deaths, ongoing efforts in this area are crucial to continue to decrease lung cancer mortality rates, Jani notes. Concurrently, there must be a heightened focus on combating air pollution through increased awareness of this issue and stricter policy measures to further reduce global lung cancer mortality rates, Jani concludes.”
Nano-immunotherapy developed to improve lung cancer treatment
“Researchers at Brigham and Women’s Hospital have developed a new nanomedicine therapy that delivers anticancer drugs to lung cancer cells and enhances the immune system’s ability to fight cancer. The team showed promising results for the new therapy in cancer cells in the lab and in mouse lung tumor models, with potential applications for improving care and outcomes for patients with tumors that have failed to respond to traditional immunotherapy.”
